How much bacteriostatic water with semaglutide?
Most research-handling protocols reconstitute a 10 mg semaglutide vial with 2 mL or 2.5 mL of bacteriostatic water. Two millilitres yields a 5 mg/mL working concentration; 2.5 mL yields 4 mg/mL. The specific volume chosen sets the per-week dose-draw math for the typical 0.25-2.4 mg weekly research dose range.
What the research literature says
Semaglutide’s clinical-trial dose range spans 0.25 mg starter doses (SUSTAIN-1, PMID 28110911) to the 2.4 mg per week dose that anchors the STEP obesity program (PMID 33567185) and the SELECT cardiovascular-outcomes trial (PMID 37952131). All clinical doses sit well below 10 mg per draw, so reconstitution-volume choice is primarily about precision at the low-dose end rather than fitting large doses into the syringe.
For a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg/mL): a 0.25 mg dose draws 5 units; 1 mg draws 20 units; 2.4 mg draws 48 units (about half of a 1 mL insulin syringe). With 2.5 mL fill (4 mg/mL), the 0.25 mg dose moves to ~6 units and the 2.4 mg dose to 60 units. Both volumes give workable precision; the 2.5 mL fill stretches the lowest dose to slightly more measurable single-digit units.
The 28-day in-use stability window after reconstitution applies to either fill volume — the preservative profile of bacteriostatic water and the peptide’s chemical-stability framework (PMID 10967427) are independent of the dilution choice.
Why this matters in research context
Most semaglutide research protocols mirror the clinical dose-titration pattern — start low (0.25 mg per week), step up at 4-week intervals, settle at a 1-2.4 mg per week maintenance dose. Reconstitution-volume choice should make the starter dose measurable to within ~10% precision on the insulin syringe used. The 2 mL and 2.5 mL fills both clear that bar; lower volumes (1 mL fill = 10 mg/mL) push the starter dose down to ~2-3 units where syringe precision falls below the 10% target. Detailed protocols are in the reconstitution guide.
Related compounds
- Semaglutide 10mg — the compound covered by this answer
- Tirzepatide 10mg — parallel dual-incretin agonist with similar reconstitution math
Related research questions
- How long does reconstituted semaglutide last?
- What is the half-life of semaglutide?
- How much bacteriostatic water with tirzepatide?
References
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260. [PMID 28110911]
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. [PMID 33567185]
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389(24):2221-2232. [PMID 37952131]
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203(1-2):1-60. [PMID 10967427]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Semaglutide is sold strictly as a research-grade reagent for laboratory and bench research applications.